

The effects of heavy metal ions, phthalates and ochratoxin A on oxidation of carcinogenic aristolochic acid I causing Balkan endemic nephropathy

Frantisek BARTA¹, Katerina LEVOVA¹, Petr HODEK¹,
Heinz H. SCHMEISER², Volker M. ARLT³, Marie STIBOROVA¹

- 1 Department of Biochemistry, Faculty of Science, Charles University in Prague, Prague, Czech Republic
- 2 Research Group Genetic Alterations in Carcinogenesis, German Cancer Research Center, Heidelberg, Germany
- 3 Analytical and Environmental Sciences Division, MRC-PHE Centre for Environment & Health, King's College London, London, United Kingdom

Correspondence to: Prof. RNDr. Marie Stiborova, DSc.
Department of Biochemistry, Faculty of Science, Charles University, Prague
Albertov 2030, 128 40 Prague 2, Czech Republic.
TEL: +420-22195121285; FAX: +420-221951283; E-MAIL: stiborov@natur.cuni.cz

Submitted: 2015-07-18 Accepted: 2015-09-09 Published online: 2015-10-15

Key words: aristolochic acid; oxidation; cytochrome P450; heavy metals;
phthalates; ochratoxin A

Neuroendocrinol Lett 2015;36(Suppl. 1):13-21 PMID: 26757129 NEL360915A01 ©2015 Neuroendocrinology Letters • www.nel.edu

Abstract

OBJECTIVES: Balkan endemic nephropathy (BEN) is a chronic progressive fibrosis associated with upper urothelial carcinoma (UUC). Aetiology of BEN is still not fully explained. Although carcinogenic aristolochic acid I (AAI) was proven as the major cause of BEN/UUC, this nephropathy is considered to be multifactorial. Hence, we investigated whether other factors considered as potential causes of BEN [a mycotoxin ochratoxin A (OTA), Cd, Pb, Se and As ions and organic compounds (i.e. phthalates) released from lignite deposits in BEN areas] can influence detoxication of AAI, whose concentrations are crucial for BEN development.

METHODS: Oxidation of AAI to 8-hydroxyaristolochic acid I (AAIa) in the presence of Cd, Pb, Se, As ions, dibutylphthalate (DBP), butylbenzylphthalate (BBP), bis(2-ethylhexyl)phthalate (DEHP) and OTA by rat liver microsomes was determined by HPLC.

RESULTS: Only OTA, cadmium and selenium ions, and BBP inhibited AAI oxidation by rat liver microsomes. These compounds also inhibited activities of CYP1A1 and/or CYP2C6/11 catalysing AAI demethylation in rat livers. Therefore, these CYP inhibitions can be responsible for a decrease in AAIa formation. When the combined effects of these compounds were investigated, the most efficient inhibition was caused by OTA combined with BBP and selenium ions.

CONCLUSION: The results show low effects of BBP, cadmium and selenium ions, and/or their combinations on AAI detoxication. No effects were produced by the other metal ions (Pb, As) and phthalates DBP and DEHP. This finding suggests that they do not influence AAI-mediated BEN development. In contrast, OTA might influence this process, by inhibition of AAI detoxication.

Abbreviations

AA	- aristolochic acid
AAI	- 8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid
AAIa	- 8-hydroxyaristolochic acid I
AAII	- 6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid
AAN	- aristolochic acid nephropathy
BBP	- butylbenzylphthalate
BEN	- Balkan endemic nephropathy
CYP	- cytochrome P450
dA-AAI	- 7-(deoxyadenosin-N ⁶ -yl)aristolactam I
DBP	- dibutylphthalate
DEHP	- bis(2-ethylhexyl)phthalate
dG-AAI	- 7-(deoxyguanosin-N ² -yl) aristolactam I
EROD	- 7-ethoxyresorufin-O-deethylase
HPLC	- high performance liquid chromatography
IARC	- International Agency for Research on Cancer
NADP+	- nicotinamide adenine dinucleotide phosphate (oxidised)
NADPH	- nicotinamide adenine dinucleotide phosphate (reduced)
NQO1	- NAD(P)H:quinone oxidoreductase
OTA	- ochratoxin A
Pb(Ac) ₂	- lead acetate
r.t.	- retention time
TP53	- tumour suppressor gene
UUC	- upper urothelial carcinoma

INTRODUCTION

Balkan endemic nephropathy (BEN) is a chronic progressive renal fibrosis affecting rural population in Bulgaria, Bosnia and Herzegovina, Romania, Croatia and Serbia along Danube river basin (Stefanovic 1983; Radanovic 2002). The unique feature of this disease is that BEN seems to be a familial, but not inherited occurring in several endemic areas (Toncheva *et al.* 1998; Radanovic 2002; Grollman 2013). Moreover, this serious disease is closely associated with upper urothelial carcinomas (UUC) of the renal pelvis and ureter (Stefanovic 1983; Jankovic *et al.* 1988; Nikolic *et al.* 2002). Although BEN has been studied for more than 50 years, aetiology of this nephropathy is still a matter of debate. There are several hypotheses suggesting that BEN/UUC is the multifactorial disease which might be caused by environmental compounds such as: (i) aristolochic acid (AA) (Ivic 1969; Hranjec *et al.* 2005; Arlt *et al.* 2002a, 2007; Grollman *et al.* 2007), (ii) mycotoxins [i.e. ochratoxin A (OTA), citrinine] (Radic *et al.* 1997; Pfohl-Leszkowicz 2009), (iii) heavy metal ions (Nichifor *et al.* 1985; Long *et al.* 2001; Karmaus *et al.* 2008) and (iv) organic compounds released from lignite deposits in the endemic areas (Feder *et al.* 1991; Tatu *et al.* 1998).

During the last decade, AA was identified as the main cause of this environmental disease (Ivic 1969; Arlt *et al.* 2002a, 2007; Grollman *et al.* 2007; Stiborova *et al.* 2008). The AA was suggested as possible cause of BEN/UUC for the first time in late 1960s (Ivic 1969). This

plant alkaloid found in *Aristolochia* species was found in wheat used for home-prepared bread (Ivic 1969; Jelakovic *et al.* 2012; Gokmen *et al.* 2013). The plant extract of AA is a mixture of structurally related nitrophenanthrene carboxylic acids whose major components are aristolochic acid I (AAI) and aristolochic acid II (AAII). AAI is supposed to be the predominant compound responsible for BEN development. AA and herbal products derived from genera *Aristolochia* have been classified by International Agency for Research on Cancer (IARC) as carcinogenic to human (Group 1) (Grosse *et al.* 2009). Furthermore, this nephrotoxic and carcinogenic agent was found to cause also another disease similar to BEN, aristolochic acid nephropathy (AAN) (Cosyns *et al.* 1994; Arlt *et al.* 2002b, 2007; Debelle *et al.* 2008; Schmeiser *et al.* 1996, 2009; Gokmen 2013).

In contrast to the finding that AAI might directly cause interstitial nephropathy, metabolic activation of this alkaloid to species forming DNA adducts is a necessary step for AAI-induced malignant transformation (Cosyns *et al.* 1994; Arlt *et al.* 2002b; Schmeiser *et al.* 1996, 2009; Chen *et al.* 2012). In organisms, AAI can be either reductively activated to *N*-acylnitrenium ion leading to AAI-DNA adduct formation or oxidatively detoxified to an *O*-demethylated product, 8-hydroxyaristolochic acid (aristolochic acid Ia, AAIa; Figure 1) (Arlt *et al.* 2002b, 2007; Grollman *et al.* 2007; Stiborova *et al.* 2014a, 2014b). The AA-DNA adducts formed from activated AAI with adenosine and guanosine residues in DNA were found in BEN and AAN patients (Schmeiser *et al.* 1996; Bieler *et al.* 1997; Arlt *et al.* 2002a). The most persistent DNA adduct, 7-(deoxyadenosin-*N*⁶-yl)-aristolactam I (dA-AAI), is proposed to cause a characteristic AT→TA transversion mutations which have been detected in the TP53 tumour suppressor gene in tissues of patients from the endemic areas. Such AT→TA transversions are responsible for tumour development in patients suffering from BEN and AAN (Arlt *et al.* 2007; Grollman *et al.* 2007; Stiborova *et al.* 2008; Hollstein *et al.* 2013). These findings indicate that the concentration of AAI in organisms is essential for both renal injury and induction of UUC initiated by activated AAI. The effective concentration of AAI in organism is dictated by its metabolism. Since AAI can be both bio-activated to reactive species forming AAI-DNA adducts resulting in cancer development and detoxified to AAIa, these reactions might significantly modulate the AAI toxic/genotoxic potential (Stiborova *et al.* 2008, 2011a, 2012, 2013b; Arlt *et al.* 2011).

A common feature of BEN/UUC is that not all individuals exposed to AAI suffer from these diseases (Arlt *et al.* 2002b, 2011; Stiborova *et al.* 2008, 2012, 2013b, 2015; Jelakovic *et al.* 2012). This phenomenon might be explained by different efficiencies of enzymes participating in metabolism of AAI and by genetic sensitivity of individuals (Stiborova *et al.* 2001, 2003, 2008, 2013b; Toncheva *et al.* 2004; Grollman 2013). Therefore, detailed understanding of enzymes involved in AAI




Fig. 1. Scheme of detoxication and bio-activation of AAI in organisms. dA-AAI, 7-(deoxyadenosin- N^6 -yl)aristolactam I; dG-AAI, 7-(deoxyguanosin- N^2 -yl)aristolactam I; UGT, UDP glucuronosyl transferase; SULT, sulfotransferase.

metabolism (activation and/or reduction) is crucial for risk assessment of AA exposure.

The major enzymes involved in reductive bio-activation of AAI are NAD(P)H:quinone oxidoreductase (NQO1) and cytochromes P450 (CYP) of the 1A sub-family in humans and mouse or rat animal models (Stiborova *et al.* 2008, 2011a, 2012, 2013b, 2014a, 2014b; Arlt *et al.* 2011; Barta *et al.* 2014). The most efficient enzymes participating in AAI detoxication are human, mouse and rat CYP1A1/2 and rat and human CYP2C (Arlt *et al.* 2011; Stiborova *et al.* 2011b, 2012, 2013b).

However, it is still not exactly known whether the other compounds suggested to be responsible for BEN development might influence the AAI-induced BEN. Hence, in this work, we investigated whether OTA, heavy metal ions and organic chemicals released from lignite deposits in the endemic areas can influence the detoxication of AAI, whose concentrations are crucial for BEN development. Heavy metal ions and organic compounds were selected according to data from epidemiologic studies (Radic *et al.* 1997; Karmaus *et al.* 2008; Pfohl-Leszkowicz 2009; Yordanova *et al.* 2010; Maharaj *et al.* 2014).

MATERIALS AND METHODS

Chemicals

AAI sodium salt, CdCl_2 , $\text{Pb}(\text{CH}_3\text{COO})_2$, Na_2SeO_3 , $\text{Na}_2\text{HASO}_4 \cdot 7\text{H}_2\text{O}$, dibutylphthalate (DBP), butylbenzylphthalate (BBP) and bis(2-ethylhexyl)phthalate (DEHP) as well as other chemicals were purchased from Sigma Chemical Co. (St. Louis MO, USA). All chemical were of 97% purity or better.

Preparation of rat hepatic microsomal fraction

Microsomes were prepared from liver of untreated Wistar rats by differential centrifugation as described previously (Stiborova *et al.* 2013a; Indra *et al.* 2014).

AAIa formation in the presence of heavy metal ions/phthalates/OTA

Incubation mixtures, in a final volume 500 μL , consisted of 100 $\text{mmol} \cdot \text{L}^{-1}$ potassium buffer (pH 7.4), NADPH-generation system (1 $\text{mmol} \cdot \text{L}^{-1}$ NADP⁺, 10 $\text{mmol} \cdot \text{L}^{-1}$ $\text{MgCl}_2 \cdot 6\text{H}_2\text{O}$, 1 U/mL glucose-6-phosphate dehydrogenase), 1–100 $\mu\text{mol} \cdot \text{L}^{-1}$ of heavy metal ions/phthalates/OTA, 0.25 mg rat hepatic micro-

somes and $10 \mu\text{mol.L}^{-1}$ AAI. CdCl_2 , $\text{Pb}(\text{CH}_3\text{COO})_2$, Na_2SeO_3 , $\text{Na}_2\text{HASO}_4 \cdot 7\text{H}_2\text{O}$ were dissolved in distilled water and OTA was dissolved in 0.1 mol.L^{-1} NaHCO_3 (pH 7) whereas phthalates were prepared in acetonitrile. Incubations with microsomes were carried out at 37°C for 10 min and AAI oxidation to AAIA was linear up to 25 min (Levova *et al.* 2011; Stiborova *et al.* 2012). Control incubations were carried out (i) without microsomes, (ii) without NADPH-generating system or (iii) without AAI. AAI and AAIA were analysed by high performance liquid chromatography (HPLC) as described (Sistkova *et al.* 2008; Levova *et al.* 2011; Stiborova *et al.* 2012).

HPLC analysis of AAIA formation

AAI and its *O*-demethylated metabolite (AAIA) were extracted from incubations with ethyl acetate ($2 \times 1 \text{ mL}$), the extracts were evaporated to dryness and the residues redissolved in $30 \mu\text{L}$ of methanol and subjected to reverse-phase HPLC. HPLC was performed with a reversed phase column (Nucleosil 100-5 C_{18} , $25 \times 4.0 \text{ mm}$, 5 mm ; Macherey-Nagel) preceded by a C-18 guard column, using a linear gradient of acetonitrile (20–60% acetonitrile in 55 min) in 100 mmol.L^{-1} triethylammonium acetate with a flow rate of 0.5 mL.min^{-1} . A Dionex HPLC pump P580 with UV/VIS UVD 170S/340S spectrophotometer detector was set at 250 nm and CHROMELEON™ 6.01 integrator was used for integration of peaks. AAIA and AAI eluted with retention times (r.t.) of 24.5 and 37.7 min, respectively. The product eluting at 24.5 min was identified as AAIA by mass spectrometry previously (Sistkova *et al.* 2008; Levova *et al.* 2011; Stiborova *et al.* 2011b).

Determination of CYP1A1/2 and CYP2C6/11 enzyme activities

In rat hepatic microsomes, CYP1A1/2 was determined by ethoxyresorufine-*O*-deethylation (EROD) (Burke *et al.* 1994). Enzyme activity of CYP1A1 was measured as

capability of Sudan I oxidising (Stiborova *et al.* 2002). CYP2C6/11 activities in rat microsomes were characterised as well: CYP2C6 was measured with diclofenac as a marker substrate (Kaphalia *et al.* 2006) and CYP2C11 activity was determined as testosterone 16α -hydroxylation (Yamazaki *et al.* 2006). The effect of heavy metal ions/phthalates/OTA on the above mentioned enzyme activities was carried out by addition of compounds tested to incubation mixtures in a final concentration of $100 \mu\text{mol.L}^{-1}$.

Statistical analyses

For statistical data analysis we used Student's *t*-test. All *p*-values are two-tailed and considered significant at the 0.001 level.

RESULTS AND DISCUSSION

Oxidation of AAI to AAIA in the presence of the heavy metal ions, phthalates and ochratoxin A

In rat microsomes, AAI was oxidised to one metabolite eluted by HPLC at r.t. of 24.5 minutes (Figure 2). This metabolite was previously identified by positive MALDI-TOF-TOF analysis as AAIA (Levova *et al.* 2011; Stiborova *et al.* 2011b). Because of a low toxicity, AAIA was considered to be the detoxication metabolite of AAI (Shibutani *et al.* 2010). The effects of compounds, which were suggested that might contribute to development of BEN/UUC, namely the heavy metal ions, phthalates and OTA, on detoxication of AAI to AAIA catalysed by rat liver microsomes are shown in Figures 3–5. Cadmium and selenium ions inhibited AAIA formation (Figures 3A,C) whereas no such effect was found in the presence of Pb^{2+} and arsenate ions (Figures 3B,D). However, the 10-times higher concentration of cadmium and selenium ions than the concentration of AAI was necessary for the significant decrease in AAI oxidation. Of phthalates examined, only butylbenzylphthalate (BBP) inhibited oxidation of AAI to AAIA




Fig. 2. HPLC of AAI (peak r.t. at 37.7 min) and AAIA metabolite (peak r.t. at 24.5 min) produced by hepatic microsomes of control (untreated) rats incubated with AAI and the NADPH-generating system. The peaks with the characterised metabolite AAIA and the parent AAI are indicated in the chromatograms.





Fig. 3. AAI oxidation to AAIA catalysed by rat hepatic microsomes in the presence of heavy metal ions present in incubation mixtures, CdCl₂ (A), Pb(CH₃COO)₂ [Pb(Ac)₂]; B), Na₂SeO₃ (C), Na₂HAsO₄·7H₂O (D). Values are given as means ± standard deviations of three experiments (n = 3). Values significantly different from incubation with buffer only: *p<0.1, **p<0.01 (Student's t-test). The incubation mixtures contained 0.5 mg.mL⁻¹ microsomal protein, 1–100 μmol.L⁻¹ heavy metal ions dissolved in distilled water, the NADPH-generating system containing 1 mmol.L⁻¹ NADP⁺, and 10 μmol.L⁻¹ AAI dissolved in distilled water (see Materials and Methods). Numbers above the columns ("F") indicate fold changes in amounts of AAIA compared to incubations without heavy metal ions.

(Figure 4B). The other two studied phthalates (DBP and DEHP) that are known as important toxic environmental pollutants (Ferguson *et al.* 2014; Yan *et al.* 2015) were without this effect (Figures 4A,C). In the case of OTA, the significant inhibition of AAI demethylation by this mycotoxin was found. The 10 and 100 μmol.L⁻¹ OTA led to a 23% and 42% decrease in AAIA formation, respectively (Figure 5). These findings are consistent with the results found in our former study which demonstrated that OTA is capable of inhibiting AAI oxidation to AAIA *in vivo* (Stiborova *et al.* 2015).

Because human population living in the endemic areas might be exposed not only to each of these compounds individually but also to their combination, in the next step of this study we investigated a combined effect of the substances that inhibited AAI oxidation,

namely, cadmium and selenium ions, BBP and OTA (Figure 6). Interestingly, although oxidation of AAI to AAIA was not influenced by a combination of BBP and OTA, all four contaminants (cadmium and selenium ions, BBP and OTA) added to incubation mixtures led to the significant inhibition of AAIA formation, by 34% (Figure 6B). In addition, the most efficient inhibition of AAI demethylation was caused by OTA combined with BBP and selenium ions, by 37% (Figure 6B). Using the other combinations, no additive effects of these combinations compared to inhibition caused by individual compounds were found. This phenomenon is now difficult to be explained. One can speculate that compounds might compete against each other, thereby decreasing the inhibition of enzymes involved in AAI oxidation or inter-molecular interactions between the



tested compounds might decrease their actual concentrations. These suggestions need, however, to be explored in further studies.

Effect of the heavy metal ions, butylbenzylphthalate and ochratoxin A on enzymatic activities of cytochromes P450.

In order to evaluate the mechanisms of inhibition of AAI oxidation in rat microsomes, the effects of the compounds found to inhibit this reaction (Figures 3–5) on activities of the major enzymes participating in AAI detoxication were analysed. Namely, the effects of cadmium and selenium ions, BBP and OTA on activi-




Fig. 5. AAI oxidation to AAla catalysed by rat hepatic microsomes in the presence of OTA dissolved in 0.1 mol.L⁻¹ NaHCO₃ (pH 7). Values are given as means ± standard deviations of three experiments (n = 3). Values significantly different from incubation with 0.1 mol.L⁻¹ NaHCO₃ (pH 7) only: ***p<0.001 (Student's t-test). The incubation mixtures contained 0.5 mg.mL⁻¹ microsomal protein, 1–100 μmol.L⁻¹ OTA, the NADPH-generating system containing 1 mmol.L⁻¹ NADP⁺, and 10 μmol.L⁻¹ AAI dissolved in distilled water (see Materials and Methods).

Fig. 4. AAI oxidation to AAla catalysed by rat hepatic microsomes in the presence of phthalates. In incubation mixtures, dibutylphthalate (DBP, A), butylbenzylphthalate (BBP, B) and bis(2-ethylhexyl)phthalate (DEHP, C) all dissolved in acetonitrile were used. Values are given as means ± standard deviations of three experiments (n = 3). Values significantly different from incubation with acetonitrile only: *p<0.1, **p<0.01 (Student's t-test). The incubation mixtures contained 0.5 mg.mL⁻¹ microsomal protein, 1–100 μmol.L⁻¹ phthalates, the NADPH-generating system containing 1 mmol.L⁻¹ NADP⁺, and 10 μmol.L⁻¹ AAI dissolved in distilled water (see Materials and Methods). Numbers above the columns ("F") indicate fold changes in amounts of AAla compared to incubations without phthalates.

ties of CYP1A and 2C6/11 enzymes were tested. The enzyme activities were determined utilising a marker substrates (see the Material and Methods section). The data shown in Table 1 demonstrate that CYP1A1 activity was inhibited mainly by Cd²⁺ and BBP; a 54 and 75% decrease in a CYP1A1 marker activity (Sudan I oxidation) was found, respectively, whereas the other tested compounds did not influence CYP1A activity. In the case of CYP2C, BBP significantly inhibited activity of CYP2C6, whereas OTA decreased activity of CYP2C11, the CYP enzyme that is predominantly expressed in rat liver (Zachařová *et al.* 2012). Based on these results, the decreased oxidation of AAI to AAla caused by tested




Fig. 6. Combined effect of cadmium and selenium ions, BBP and OTA on AAI detoxication to AAla. Incubations with CdCl₂, Na₂SeO₃ and OTA (A) and in combination of these compounds with BBP (B) were carried out. Values are given as means \pm standard deviations of three experiments ($n = 3$). Values significantly different from incubation with buffer/acetonitrile only: * $p < 0.1$, ** $p < 0.01$, *** $p < 0.001$ (Student's t-test). The incubation mixtures contained 0.5 mg.mL⁻¹ microsomal protein, 100 μ mol.L⁻¹ CdCl₂, Na₂SeO₃, dissolved in distilled water, OTA dissolved in 0.1 mol.L⁻¹ NaHCO₃ (pH 7) or BBP dissolved in acetonitrile, the NADPH-generating system containing 1 mmol.L⁻¹ NADP⁺, and 10 μ mol.L⁻¹ AAI dissolved in distilled water (see Materials and Methods). Numbers above the columns ("F") indicate fold changes in amounts of AAla compared to incubations without the above mentioned compounds.

contaminants might be caused by decreased enzyme activities of these CYPs.

Several studies suggested that BEN and AAN may be the same diseases which differ slightly (Grollman

et al. 2009). One of the differences between BEN and AAN is that whereas BEN is characterised by an insidious onset and slow gradual progression (Grollman *et al.* 2007; Stiborova *et al.* 2008; Jelakovic *et al.* 2012.), AAN is defined as rapidly progressive interstitial renal fibrosis (Vanherweghem *et al.* 1993). One of the reasons responsible for this difference seems to be a different exposure schedule of patients; chronic exposure to low concentrations of AA of population living in BEN areas, whereas exposure to high doses of individuals in which AAN was developed (Gokmen *et al.* 2013). However, based on the results found in the present and our former (Stiborova *et al.* 2015) studies, this difference might also follow from inhibitions of AAI detoxication by the compounds such as heavy metal ions (cadmium and selenium), phthalates (BBP) and OTA, the substances to which BEN/UUC patients are exposed. Although BBP and cadmium and selenium ions were shown to be present in water and lignite samples in the BEN areas (Karmaus *et al.* 2008; Maharaj *et al.* 2014), there is still not enough information on their exact concentrations in these samples. Therefore, we cannot evaluate whether their concentrations found in this study to inhibit AAI detoxication are valid for the BEN development. Nevertheless, even though there is a study which has demonstrated that a role of heavy metal ions in BEN/UUC development is negligible (Karmaus *et al.* 2008), because of inhibition of AAI detoxication by cadmium and selenium ions found in this work, the participation of the chronic exposure to these ions in the AAI-mediated BEN development cannot be excluded. Chronic OTA intake is common in many populations ranging up to 25 ng.kg⁻¹ body weight and day, and OTA is detectable in plasma in BEN patients at levels up to 3.9 ng.mL⁻¹ (Yordanova *et al.* 2010) but also in healthy controls. The doses to which humans are exposed are lower than the OTA concentrations found in this study to inhibit AAI detoxication. However, drug-drug interactions between AAI and OTA at lower but chronic and life-long doses of human exposure in BEN areas may be different. Therefore, OTA, because of its potency to

Tab. 1. The effects of cadmium and selenium ions, BBP, and OTA on enzyme activity of rat CYP1A and 2C.

Pollutant	EROD activity	Sudan I oxidation	Diclofenac 4'-hydroxylation	Testosterone 16 α -hydroxylation
	(CYP1A) ^a	(CYP1A1)	(CYP2C6)	(CYP2C11)
CdCl ₂	83 \pm 0.09*	46 \pm 4.27***	89 \pm 0.44*	100 \pm 6.43
Na ₂ SeO ₃	95 \pm 0.83	100 \pm 2.62	94 \pm 5.59	82 \pm 1.01**
OTA	100 \pm 7.50	99 \pm 4.93	NE ^b	18 \pm 1.24***
BBP	83 \pm 1.24*	25 \pm 1.27***	7 \pm 0.26***	68 \pm 12.48**

Data are expressed as % of control without pollutants. Values in the table are averages \pm standard deviations of three experiments ($n = 3$). The incubation mixtures contained 0.5 mg.mL⁻¹ microsomal protein, 10 μ mol.L⁻¹ AAI (dissolved in distilled water), the NADPH-generating system containing 1 mmol.L⁻¹ NADP⁺, and 100 μ mol.L⁻¹ pollutant [heavy metal ions dissolved in distilled water, OTA dissolved in 0.1 mol.L⁻¹ NaHCO₃ (pH 7) or BBP dissolved in acetonitrile] (see Materials and Methods). Values significantly different from control incubations without pollutants; * $P < 0.1$, ** $P < 0.01$, *** $P < 0.001$ (Student's t-test). ^aIsoforms of CYP whose enzyme activity is measured are shown in brackets.

^bNE, no effect.

increase actual concentrations of AAI by inhibition of its detoxication, may enhance the development of AAI-induced UUC in BEN patients.

CONCLUSIONS

The results found in this study demonstrate that AAI detoxication to AAIA is inhibited by OTA, phthalate BBP and partially also by cadmium and selenium ions. Such inhibition is caused by inhibition of the CYP1A1 and 2C enzymes that catalyse this reaction. Even though these inhibitions are not fatal, their contributions to the AAI-mediated development of BEN/UUC, considering mainly the chronic exposure of population living in the endemic areas to these pollutants, cannot be ruled out.

ACKNOWLEDGEMENTS

The authors thank Grant Agency of Czech Republic (grant P301/12/G163) and Charles University in Prague (grant GAUK 570513).

REFERENCES

- Arlt VM, Ferluga D, Stiborova M, Pfohl-Leszkwicz A, Vukelic M, Ceovic S, *et al.* (2002a). Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer? *Int J Cancer*. **101**: 500–502.
- Arlt VM, Stiborova M and Schmeiser HH (2002b). Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. *Mutagenesis*. **17**: 265–277.
- Arlt VM, Stiborova M, vom Brocke J, Simoes ML, Lord GM, Nortier JL, *et al.* (2007). Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. *Carcinogenesis*. **28**: 2253–2261.
- Arlt VM, Levova K, Barta F, Shi Z, Evans JD, Frei E, *et al.* (2011). Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in *Cyp1a1*^{-/-}, *Cyp1a2*^{-/-}, and *Cyp1a1/1a2*^{-/-} mice. *Chem Res Toxicol*. **24**: 1710–1719.
- Barta F, Levova K, Frei E, Schmeiser HH, Arlt VM, Stiborova M (2014). The effect of aristolochic acid I on expression of NAD(P)H:quinone oxidoreductase in mice and rats – a comparative study. *Mutat Res Genet Toxicol Environ Mutagen*. **768**: 1–7.
- Bieler CA, Stiborova M, Wiessler M, Cosyns JP, van Ypersele de Strihou C, *et al.* (1997). ³²P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. *Carcinogenesis*. **18**: 1063–1067.
- Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT (1994). Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. *Biochem Pharmacol*. **48**: 923–936.
- Chen CH, Dickman KG, Moriya M, Zavadil J, Sidorenko VS, Edwards KL, *et al.* (2012). Aristolochic acid-associated urothelial cancer in Taiwan. *Proc Natl Acad Sci USA*. **109**: 8241–8246.
- Cosyns JP, Jadoul M, Squifflet JP, De Plaen JF, Ferluga D, van Ypersele de Strihou C (1994). Chinese herbs nephropathy: a clue to Balkan endemic nephropathy? *Kidney Int*. **45**: 1680–1688.
- Debelle FD, Vanherweghem JL, Nortier JL (2008). Aristolochic acid nephropathy: a worldwide problem. *Kidney Int*. **74**: 158–169.
- Feder GL, Radovanovic Z, Finkelman RB (1991). Relationship between weathered coal deposits and the etiology of Balkan endemic nephropathy. *Kidney Int*. **40**(Suppl. 34): 59–511.
- Ferguson KK, McElrath TF, Meeker JD (2014). Environmental phthalate exposure and preterm birth. *JAMA Pediatr*. **168**: 61–67.
- Gokmen MR, Cosyns JP, Arlt VM, Stiborova M, Phillips DH, Schmeiser HH, *et al.* (2013). The epidemiology, diagnosis, and management of aristolochic acid nephropathy: a narrative review. *Ann Intern Med*. **158**: 469–477.
- Grollman AP (2013). Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. *Environ Mol Mutagen*. **54**: 1–7.
- Grollman AP, Scarborough J, Jelakovic B (2009). Aristolochic acid nephropathy: An environmental and iatrogenic disease. In: Fishbein J, editor. *Advances in Molecular Toxicology 3*, Amsterdam, Elsevier. p. 211–222.
- Grollman AP, Shibutani S, Moriya M, Miller F, Wu L, Moll U, *et al.* (2007). Aristolochic acid and the etiology of endemic (Balkan) nephropathy. *Proc Natl Acad Sci USA*. **104**: 12129–12134.
- Grosse Y, Baan R, Straif K, Secretan B, El Ghissassi F, Bouvard V, *et al.* (2009). A review of human carcinogens-Part A: pharmaceuticals. *Lancet Oncol*. **10**: 13–14.
- Hollstein M, Moriya M, Grollman AP, Olivier M (2013). Analysis of TP53 mutation spectra reveals the fingerprint of the potent environmental carcinogen, aristolochic acid. *Mutat Res*. **753**: 41–49.
- Hranjec T, Kovac A, Kos J, Mao W, Chen JJ, Grollman AP, *et al.* (2005). Endemic nephropathy: the case for chronic poisoning by aristolochia. *Croat Med J*. **46**: 116–125.
- Indra R, Moserova M, Kroftova N, Sulc M, Martinkova M, Adam V, *et al.* (2014). Modulation of human cytochrome P450 1A1-mediated oxidation of benzo[a]pyrene by NADPH:cytochrome P450 oxidoreductase and cytochrome b₅. *Neuroendocrinol Lett*. **35**(Suppl. 2): 105–113.
- Ivic M (1969). The problem of etiology of endemic nephropathy. *Lijec Vjesn*. **91**: 1273–1281.
- Jankovic S, Marinkovic J, Radovanovic Z (1988). Survival of the upper-urothelial-cancer patients from the Balkan nephropathy endemic and nonendemic areas. *Eur Urol*. **15**: 59–61.
- Jelakovic B, Karanovic S, Vukovic-Lela I, Miller F, Edwards KL, Nikolic J, *et al.* (2012). Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. *Kidney Int*. **81**: 559–567.
- Kaphalia L, Kaphalia BS, Kumar S, Kanz MF, Treinen-Moslen M (2006). Efficient high performance liquid chromatograph/ultraviolet method for determination of diclofenac and 4'-hydroxydiclofenac in rat serum. *J Chromatogr B Analyt Technol Biomed Life Sci*. **830**: 23–237.
- Karmaus W, Dimitrov P, Simeonov V, Tsoleva S, Bonev A, Georgieva R (2008). Metals and kidney markers in adult offspring of endemic nephropathy patients and controls: a two-year follow-up study. *Environ Health*. **7**: 1–11.
- Levova K, Moserová M, Kotrbová V, Sulc M, Henderson CJ, Wolf CR, *et al.* (2011). Role of cytochromes P450 1A1/2 in detoxication and activation of carcinogenic aristolochic acid I: studies with the hepatic NADPH:cytochrome P450 reductase null (HRN) mouse model. *Toxicol Sci*. **121**: 43–56.
- Long DT, Icopini G, Ganey V, Petropoulos E, Havezov I, Voice T, *et al.* (2001). Geochemistry of Bulgarian soils in villages affected and not affected by Balkan endemic nephropathy: a pilot study. *Int J Occup Med Environ Health*. **14**: 193–196.
- Maharaj SVM, Orem WH, Tatu CA, Lerch HE, Szilagyi DN (2014). Organic compounds in water extracts of coal: links to Balkan endemic nephropathy. *Environ Geochem Health*. **36**: 1–17.
- Nichifor E, Balea M, Rusu G, Melencu M, Ghiordanescu N, Cristescu I, *et al.* (1985). Studies on the familial character of endemic Balkan nephropathy. Possible role of the toxic hydric factor in the determination of "familial agglomerations" in endemic Balkan nephropathy. *Med Interne*. **23**: 229–237.
- Nikolic J, Djokic M, Crnomarkovic D, Marinkovic J (2002). Upper urothelial tumors and Balkan endemic nephropathy-dose responsible diseases. *Facta Univ Ser Med Biol*. **9**: 114–118.
- Pfohl-Leszkwicz A (2009). Ochratoxin A and aristolochic acid involvement in nephropathies and associated urothelial tract tumours. *Arh Hig Rada Toksikol*. **60**: 465–483.
- Radic B, Fuchs R, Peraica M, Lucic A (1997). Ochratoxin A in human sera in the area with endemic nephropathy in Croatia. *Toxicol Lett*. **91**: 105–109.

- 33 Radovanovic Z (2002). Epidemiology and etiology of endemic nephropathy. In: Radovanovic Z, Sindi M, Polenakovic M, Djukanovic Lj, Petronic V, editors. *Endemic Nephropathy*. Zavod za zbenike i nastavna sredstva. Belgrade. p. 22–135.
- 34 Schmeiser HH, Bieler CA, Wiessler M, van Ypersele de Strihou C, Cosyns JP (1996). Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. *Cancer Res.* **556**: 2025–2028.
- 35 Schmeiser HH, Stiborova M, Arlt VM (2009). Chemical and molecular basis of the carcinogenicity of Aristolochia plants. *Curr Opin Drug Discov Devel.* **12**: 141–148.
- 36 Shibutani S, Bonala RR, Rosenquist T, Rieger R, Suzuki N, Johnson F, *et al.* (2010). Detoxification of aristolochic acid I by *O*-demethylation: less nephrotoxicity and genotoxicity of aristolochic acid Ia in rodents. *Int J Cancer.* **127**: 1021–1027.
- 37 Sistkova J, Hudecek J, Hodek P, Frei E, Schmeiser HH, Stiborova M (2008). Human cytochromes P450 1A1 and 1A2 participate in detoxication of carcinogenic aristolochic acid. *Neuroendocrinol Lett.* **29**: 733–737.
- 38 Stefanovic V (1983). Diagnostic criteria for endemic (Balkan) nephropathy. In: Strahinjic S, Stefanovic V, editors. *Current research in endemic (Balkan) nephropathy*. University Press, Nis. p. 351–363.
- 39 Stiborova M, Barta F, Levova K, Hodek P, Frei E, Arlt VM, *et al.* (2015). The influence of ochratoxin A on DNA adduct formation by the carcinogen aristolochic acid in rats. *Arch Toxicol.* Doi 10.1007/s00204-014-1360-1.
- 40 Stiborova M, Cerna V, Moserova M, Arlt VM and Frei E (2013a). The effect of benzo[a]pyrene on metabolic activation of anticancer drug ellipticine in mice. *Neuroendocrinol Lett.* **34**(Suppl. 2): 43–54.
- 41 Stiborova M, Frei E, Wiessler M, Schmeiser HH (2001). Human enzymes involved in metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. *Chem Res Toxicol.* **14**: 1128–1137.
- 42 Stiborova M, Frei E, Sopko B, Sopkova K, Markova V, Lankova M, *et al.* (2003). Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. *Carcinogenesis.* **24**: 1695–1703.
- 43 Stiborova M, Frei E, Arlt VM, Schmeiser HH (2008). Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. *Mutat Res.* **658**: 55–67.
- 44 Stiborova M, Frei E, Arlt VM, Schmeiser HH (2014a). Knock-out and humanized mice as suitable tools to identify enzymes metabolizing the human carcinogen aristolochic acid. *Xenobiotica.* **44**: 135–145.
- 45 Stiborova M, Levova K, Barta F, Shi Z, Frei E, Schmeiser HH, *et al.* (2012). Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2. *Toxicol Sci.* **125**: 345–358.
- 46 Stiborova M, Levova K, Barta F, Sulc M, Frei E, Arlt VM, *et al.* (2014b). The influence of dicoumarol on the bioactivation of the carcinogen aristolochic acid I in rats. *Mutagenesis.* **29**: 189–200.
- 47 Stiborova M, Mares J, Frei E, Arlt VM, Martinek V, Schmeiser HH (2011a). The human carcinogen aristolochic acid i is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the contribution of acetyltransferases or sulfotransferases. *Environ Mol Mutagen.* **52**: 448–459.
- 48 Stiborova M, Mares J, Levova K, Pavlickova J, Barta F, Hodek P, *et al.* (2011b). Role of cytochromes P450 in metabolism of carcinogenic aristolochic acid I: evidence of their contribution to aristolochic acid I detoxication and activation in rat liver. *Neuroendocrinol Lett.* **32**(Suppl. 1): 121–130.
- 49 Stiborova M, Martinek V, Rydlova H, Hodek P, Frei E (2002). Sudan I is a potential carcinogen for humans: evidence for its metabolic activation and detoxication by human recombinant cytochrome P450 1A1 and liver microsomes. *Cancer Res.* **62**: 5678–5684.
- 50 Stiborova M, Martinek V, Frei E, Arlt VM, Schmeiser HH (2013b). Enzymes metabolizing aristolochic acid and their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. *Curr Drug Metab.* **14**: 695–705.
- 51 Tatu CA, Orem WH, Finkelman RB, Feder GL (1998). The etiology of Balkan endemic nephropathy: still more questions than answers. *Environ Health Perspect.* **106**: 689–700.
- 52 Toncheva D, Dimitrov T, Stojanova S (1998). Etiology of Balkan endemic nephropathy: a multifactorial disease? *Eur J Epidemiol.* **14**: 389–394.
- 53 Toncheva DI, Von Ahsen N, Atanasova SY, Dimitrov TG, Armstrong VW, Oellerich M (2004). Identification of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. *J Nephrol.* **17**: 384–389.
- 54 Vanherweghem JL, Depierreux M, Tielemans C, Abramowicz D, Dratwa M, Jadoul M, *et al.* (1993). Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. *Lancet.* **341**: 387–391.
- 55 Yan Z, Wang W, Zhou J, Yi X, Zhang J, Wang X, *et al.* (2015). Screening of high phytotoxicity priority pollutants and their ecological risk assessment in China's surface waters. *Chemosphere.* **128**: 28–35.
- 56 Yamazaki H, Shimizu M, Nagashima T, Minoshima M, Murayama N (2006). Rat cytochrome P450 2C11 in liver microsomes involved in oxidation of anesthetic agent propofol and deactivated by prior treatment with propofol. *Drug Metab Dispos.* **34**: 1803–1805.
- 57 Yordanova P, Wilfried K, Tsoleva S, Dimitrov P (2010). Ochratoxin A and β 2-microglobulin in BEN patients and controls. *Toxins (Basel).* **2**: 780–792.
- 58 Zachařová A, Siller M, Spičaková A, Anzenbacherová E, Skottová N, Anzenbacher P, *et al.* (2012). Rosuvastatin suppresses the liver microsomal CYP2C11 and CYP2C6 expression in male Wistar rats. *Xenobiotica.* **42**: 731–736.